All In Biotech

Drug Trial Radar · NCT03178552

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 22, 2017

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • AlectinibDrug

    Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.

  • AtezolizumabDrug

    Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).

  • PemetrexedDrug

    Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.

  • CisplatinDrug

    Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.

  • CarboplatinDrug

    Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.

  • GemcitabineDrug

    Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).

  • EntrectinibDrug

    Participants will receive entrectinib 600 mg orally QD.

  • CobimetinibDrug

    Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.

  • VemurafenibDrug

    Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.

  • BevacizumabDrug

    Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.

  • DivarasibDrug

    Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.

  • DocetaxelDrug

    Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
  2. Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
  3. Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
  4. Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
  5. Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1Time frame: Month 12
  6. Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
  7. Cohort G: Incidence of Adverse Events (AEs)Time frame: Baseline to last dose of study treatment + 30 days or until initiation of new anticancer therapy, whichever occurs first (up to approximately 6 years)

Locations

161 sites in 27 countries. Site status is shown where the registry gives one.

  • UC Davis

    Sacramento, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • SCRI Florida Cancer Specialists South

    Fort Myers, Florida

  • Florida Cancer Specialist, North Region

    St. Petersburg, Florida

  • University of Kentucky

    Lexington, Kentucky

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Weill Cornell Medical College-New York Presbyterian Hospital

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Oregon HSU

    Portland, Oregon

  • St. Luke's University Health network

    Bethlehem, Pennsylvania

  • Sarah Cannon Research Institute / Tennessee Oncology

    Chattanooga, Tennessee

  • Fundación CENIT para la Investigación en Neurociencias

    Buenos Aires, Argentina

  • Hospital Italiano

    Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Ashford Cancer Center Research

    Kurralta Park, South Australia, Australia

  • UZ Brussel

    Brussels, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Instituto Nacional de Cancer - INCa

    Rio de Janeiro, Brazil

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, Canada

  • William Osler Health System Brampton Civic Hospital

    Brampton, Ontario, Canada

  • London Health Sciences Centre · Victoria Hospital

    London, Ontario, Canada

  • Lakeridge Health Center

    Oshawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • IUCPQ (Hôpital Laval)

    Québec, Quebec, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

  • Bradford Hill Centro de Investigaciones Clinicas

    Recoleta, Chile

  • Beijing Cancer Hospital

    Beijing, China

  • Hunan Cancer Hospital

    Changsha, China

  • The second Xiangya hospital of central south university

    Changsha, China

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.